Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Elastic NV (ESTC) vs Heron Therapeutics Inc (HRTX) Price & Performance

Elastic NVTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Elastic NV vs Heron Therapeutics Inc — how do they compare? Elastic NV trades at $62.04 (market cap $6.47B), while Heron Therapeutics Inc trades at $0.48 (market cap $84.50M). The key difference: Elastic NV is far larger — about 76.6× Heron Therapeutics Inc's market cap, and Elastic NV is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

ESTCHRTX
Market Cap
$6.47B$84.50M
Sector
TechnologyHealth
52-Week High
$94.47$2.02
52-Week Low
$43.30$0.39
Enterprise Value
$5.69B$182.40M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Elastic NV

Elastic (ESTC) trades at $62.84, up 0.83% on the day, with a bullish technical signal from moving averages. The company shows strong profitability metrics with a 76.07% gross margin and 21.14% net margin, though current earnings show a net loss. Recent news highlights Elastic Security achieving a 100% malware protection score (Business Wire, July 15, 2026), while multiple law firm investigations create headline risk.

The outlook is mixed: analyst consensus is strongly bullish with a $73 price target and no sell ratings, but high EV/EBITDA (164.13) suggests premium valuation. Key opportunities include consistent earnings beats and leadership in security markets, while risks include ongoing legal investigations and the transition to profitability from current net losses.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, up 13.93% today, showing volatile momentum amid mixed technical signals. The company maintains strong gross margins of 71.12% but struggles with profitability, posting a net loss of $20.20 million in 2025. Recent Q1 2026 earnings missed expectations with a $0.04 loss per share, though management reaffirmed full-year guidance. Analyst consensus remains overwhelmingly bullish with 94.74% buy ratings, contrasting with a recent Zacks Strong Sell designation.

HRTX presents a high-risk opportunity with significant analyst support but persistent financial challenges. The bullish sentiment stems from potential patent developments and commercial execution, while risks include ongoing losses, competitive pressures, and the discrepancy between analyst optimism and recent negative ratings. The stock's current valuation at 0.49x sales appears reasonable if the company can achieve profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Elastic NV

Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.

Read more on ESTC

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX